Delving into the Latest Updates on MN-08 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

NMDA receptor

Action

antagonists

Mechanism

NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesRespiratory Diseases+ [2]

Active Indication

Essential HypertensionAlzheimer DiseasePulmonary Arterial Hypertension+ [2]

Inactive Indication

Familial Primary Pulmonary Hypertension

Originator Organization

Guangzhou Magpie Pharmaceuticals Co., Ltd.

Active Organization

Guangzhou Magpie Pharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study in two ascending dose cohorts of healthy subjects. The primary objective of the trial is to assess the safety and tolerability of multiple doses of MN-08 tablet administered for 6.5 consecutive days in healthy subjects.

Start Date01 Sep 2025

Sponsor / Collaborator

Guangzhou Magpie Pharmaceuticals Co., Ltd.

ChiCTR2400092362

/ RecruitingPhase 2IIT

A multi-center,parallel,open, phase ?a clinical trial study of MN-08 tablets in subjects with mild to moderate hypertension

Start Date10 Apr 2024

Sponsor / Collaborator-

CTR20234198

/ RecruitingPhase 2

MN-08片在轻中度高血压受试者中有效性与安全性的多中心、平行、开放、Ⅱa 期临床试验

[Translation] A multicenter, parallel, open, phase IIa clinical trial of the efficacy and safety of MN-08 tablets in subjects with mild to moderate hypertension

主要试验目的：评价 MN-08片治疗2周对轻中度高血压受试者舒张压的剂量反应次要试验目的：1、评价 MN-08片治疗第7天或第14天，轻中度高血压受试者中如下指标的剂量反应：血压较基线变化的绝对值，血压控制的有效率和达标率。2、评价 MN-08片治疗14天对轻中度高血压受试者24 h 动态血压监测指标的剂量反应。3、MN-08片在轻中度高血压受试者中的安全性和耐受性。4、MN-08片口服给药在轻中度高血压受试者中的药代动力学特征。

[Translation]

Primary study objective: To evaluate the dose response of MN-08 tablets for 2 weeks on diastolic blood pressure in subjects with mild to moderate hypertension Secondary study objectives: 1. To evaluate the dose response of MN-08 tablets on the following indicators in subjects with mild to moderate hypertension on the 7th or 14th day of treatment: absolute value of blood pressure change from baseline, effective rate of blood pressure control and target achievement rate. 2. To evaluate the dose response of MN-08 tablets for 14 days on 24-hour dynamic blood pressure monitoring indicators in subjects with mild to moderate hypertension. 3. Safety and tolerability of MN-08 tablets in subjects with mild to moderate hypertension. 4. Pharmacokinetic characteristics of oral MN-08 tablets in subjects with mild to moderate hypertension.

Start Date10 Apr 2024

Sponsor / Collaborator

Guangzhou Magpie Pharmaceuticals Co., Ltd.

100 Clinical Results associated with MN-08

Login to view more data

100 Translational Medicine associated with MN-08

Login to view more data

100 Patents (Medical) associated with MN-08

Login to view more data

6

Literatures (Medical) associated with MN-08

01 Jul 2025·Neuropharmacology

Multi-functional memantine nitrate attenuated cognitive impairment in models of vascular dementia and Alzheimer's disease through neuroprotection and increased cerebral blood flow

Article

Author: Sun, Minghua ; Xie, Ningqing ; Zhang, Gaoxiao ; Wang, Yuqiang ; Sun, Yewei ; Wu, Liangmiao ; Huang, Chunhui ; Guo, Baojian ; Zhang, Guiliang ; Shi, Changzheng ; Zhang, Zaijun ; Zhang, Kexin ; Chen, Guangying ; Man Hoi, Maggie Pui

Alzheimer's disease (AD) and vascular dementia (VaD) are two prevalent forms of dementia. VaD is linked to cerebrovascular lesions, such as those from white matter ischemia and chronic cerebral hypoperfusion, which can also occur in AD. Nitric oxide (NO) regulates cerebral blood flow (CBF) in the central nervous system. Memantine is an NMDA receptor antagonist approved for AD treatment. This study investigated the efficacy and molecular mechanism of MN-08, a novel memantine nitrate, in one VaD model (2VO) and two AD models (APP/PS1 mice and Aβ1-42-induced mice). MN-08 increased CBF, ameliorated cognitive and memory functions in VaD and AD, and was more effective than memantine. MN-08 increased the survival rate of CA1 neurons and mitigated white matter lesions and axonal damage. Moreover, MN-08 protected neurons from OGD-induced loss and promoted axonal outgrowth in the hippocampus by upregulating phosphorylated Akt (p-Akt), glycogen synthase kinase-3β (p-GSK3β), and high-molecular-weight neurofilaments (p-NFH). The beneficial effects of MN-08 were attenuated by carboxy-PTIO, a potent NO scavenger, suggesting that MN-08-derived NO may alleviate cognitive impairment from cerebral hypoperfusion. Taken together, our studies demonstrate that MN-08 is a promising therapeutic agent for the treatment of dementia including VaD and AD.

01 Dec 2022·Biomedicine & Pharmacotherapy

Memantine nitrate MN-08 suppresses NLRP3 inflammasome activation to protect against sepsis-induced acute lung injury in mice

Article

Author: Hu, Huihui ; Zhang, Zaijun ; Sun, Yewei ; Zhang, Kexin ; Wang, Yuqiang ; Jiang, Houde ; Zhang, Gaoxiao ; Yi, Peng

Sepsis is a life-threatening organ dysfunction with devastating consequences, prominent among which is lung damage. Memantine, an N-methyl-D-aspartic acid receptor (NMDAR) antagonist, is able to alleviate acute lung injury (ALI). Nitric oxide (NO) suppresses NLRP3 inflammasome activation against lipopolysaccharide (LPS)-induced septic shock. MN-08, a novel nitrate derivative of memantine, possesses both the ability to antagonize NMDAR and release NO. In the present study, we aimed to investigate the protective effects of MN-08 against LPS-induced systemic inflammation and septic lung injury in mice, and to explore the underlying mechanisms of MN-08 in LPS-induced mice and THP-1 macrophages. MN-08 significantly increased the survival rate of septic mice, alleviated LPS-induced sepsis in mice via improving systemic inflammatory response syndrome and immune dysfunction, and attenuated pulmonary injury and inflammatory infiltration. More importantly, the therapeutic benefit of MN-08 for sepsis was greater than that of memantine and dexamethasone. Mechanistically, MN-08 exerted anti-inflammatory activity through inhibiting nuclear translocation of NF-κB, activation of the MAPK signaling pathway and the signaling transduction of STAT3/NF-κB. In addition, MN-08 suppressed NLRP3 inflammasome activation. Taken together, our studies demonstrate that MN-08 may be a promising therapeutic agent for sepsis-induced acute lung injury.

01 Jun 2021·HypertensionQ1 · MEDICINE

Correction to: Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling

Q1 · MEDICINE

Article

Author: Xie, Guoqing ; Wu, Liangmiao ; Gao, FangFang ; Zhang, Gaoxiao ; Wang, Yuqiang ; Liu, Zheng ; Zha, Ling ; Zhang, Zaijun ; Chen, Guangying ; Sun, Yewei ; Zhang, Zhixiang ; Luo, Fangcheng

100 Deals associated with MN-08

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 2	China	Guangzhou Magpie Pharmaceuticals Co., Ltd.	10 Apr 2024
Alzheimer Disease	Phase 2	China	Guangzhou Magpie Pharmaceuticals Co., Ltd.	30 Nov 2022
Pulmonary Arterial Hypertension	Phase 2	China	Guangzhou Magpie Pharmaceuticals Co., Ltd.	31 Dec 2021
Dementia, Vascular	IND Approval	China	Guangzhou Magpie Pharmaceuticals Co., Ltd.	27 Nov 2023
Glaucoma, Open-Angle	IND Approval	China	Guangzhou Magpie Pharmaceuticals Co., Ltd.	09 Jun 2022
Familial Primary Pulmonary Hypertension	Preclinical	China	Guangzhou Magpie Pharmaceuticals Co., Ltd.	03 Dec 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SFN2024	Not Applicable	Alzheimer Disease	-	MN-08	muxsomwzks(qxopqiwdgz) = szibsbejsj segpveljtr (hcarhhjaqg )	-	05 Oct 2024
				Tadalafil	muxsomwzks(qxopqiwdgz) = ozfyrubhmb segpveljtr (hcarhhjaqg )